Pediatric Praziquantel Consortium

Pediatric Praziquantel Consortium invited to 53rd Congress of the Brazilian Society of Tropical Medicine

14 July 2017

The Pediatric Praziquantel Consortium continues to play a primary role in the fight against schistosomiasis.  The upcoming 53rd MedTrop Congress (Aug. 27-30) in Brazil has invited the Consortium to join the roundtable discussion about ‘Advances in Knowledge about Schistosomiasis’.

Congratulations to GHIT Fund on securing over US$200 Million to its replenishment

06 June 2017

The Global Health Innovative Technology Fund (GHIT Fund), which financially supports the Pediatric Praziquantel Consortium, announced last week that it has secured commitments of over US$200 million to its replenishment for its next phase of work. 

A story of schistosomiasis infection in Ghana

A story of schistosomiasis infection in Ghana. 
Video credit: Shelly Xie



Our vision is to reduce the global disease burden of schistosomiasis by addressing the medical need of infected preschool-age children including infants and toddlers.

Read more


Our mission is to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in preschool-age children.

Read more

Development program

Soon after its formation, the consortium established a pediatric drug development program, divided into two major steps: preclinical development, and clinical development.

Read more

The pediatric formulation

A new child-appropriate praziquantel formulation is essential for treating children under 6 years of age. This formulation that aims to use small, orally dispersible tablets with an acceptable taste. 

Read more